EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.
ConditionMigraine Disorders
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorIRCCS San Raffaele Roma
About this trial
The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.
Eligibility criteria
Qualifiers
Age between 18 and 75 years;
Males and females;
Willingness to sign the informed consent;
High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;
Disqualifiers
Other headaches different than migraine;
Known intolerance to eptinezumab or eccipients;
Current treatment with other mAbs;
Vascular disease or Raynaud.
Trial design
Treatments tested in this trial
- Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov